<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-20152" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Cryptococcal Meningitis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Pescador Ruschel</surname>
            <given-names>Marco A.</given-names>
          </name>
          <aff>Medical Center Santa Rita</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Thapa</surname>
            <given-names>Bicky</given-names>
          </name>
          <aff>Cleveland Clinic</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Marco Pescador Ruschel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Bicky Thapa declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-20152.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Cryptococcosis is an opportunistic infection that causes more than 100,000 HIV-related deaths each year. Although the infection is usually HIV-related, it is also seen in other conditions, such as in patients under immunosuppressive treatments or patients with organ failure syndromes, organ transplants, innate immunologic problems, common variable immunodeficiency syndrome, and hematological disorders. This activity outlines the pathophysiology, evaluation, and management of cryptococcal meningitis and highlights the role of the interprofessional team in the management of these patients.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology of cryptococcal meningitis.</p></list-item><list-item><p>Outline the presentation of a patient with cryptococcal meningitis.</p></list-item><list-item><p>Describe the treatment and management options available for cryptococcal meningitis.</p></list-item><list-item><p>Explain interprofessional team strategies for improving care coordination and communication to advance the treatment of cryptococcal meningitis and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20152&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20152">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-20152.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Cryptococcosis is an important opportunistic infection that causes more than 100,000 HIV-related deaths each year. It was named the Busse-Buschke disease because of its first description by Otto Busse and Abraham Buschke in 1894.<xref ref-type="bibr" rid="article-20152.r1">[1]</xref></p>
        <p>Even though the infection is usually HIV-related, in many centers (especially in developed countries), most of the non-HIV-related cases include patients under immunosuppressive treatments or with organic failure syndromes, transplants, innate immunological problems, common variable immunodeficiency syndrome, and hematological disorders.<xref ref-type="bibr" rid="article-20152.r2">[2]</xref></p>
      </sec>
      <sec id="article-20152.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>There are more than 50 species of Cryptococcus;&#x000a0; <italic toggle="yes">C. neoformans</italic> and <italic toggle="yes">C. gattii&#x000a0;</italic>cause the majority of infections,&#x000a0;and some consider them the only pathogens in humans.</p>
        <p><italic toggle="yes">C. neoformans</italic> is an encapsulated yeast that can be found in aged pigeon droppings&#x000a0;which causes mild infections, from airway colonization or asymptomatic ones in laboratory workers to severe infections like meningitis or disseminated disease. It is the most common species from the Cryptococcus genre in our region (Brazil)&#x000a0;and other temperate weathers around the world.&#x000a0;<xref ref-type="bibr" rid="article-20152.r3">[3]</xref></p>
        <p>The major predisposing factor to cryptococcal infection is HIV; however, the predisposing factors in non-HIV patients are as follows<xref ref-type="bibr" rid="article-20152.r4">[4]</xref>:</p>
        <p>
<bold>Syndromes and Autoantibodies</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Idiopathic CD4 lymphopenia</p>
          </list-item>
          <list-item>
            <p>Pulmonary alveolar proteinosis with autoantibodies to granulocyte-macrophage colony stimulating factor</p>
          </list-item>
          <list-item>
            <p>Autoantibodies to interferon-gamma</p>
          </list-item>
        </list>
        <p>
<bold>Monogenic Disorders </bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Primary immunodeficiency owing to <italic toggle="yes">GATA2 </italic>mutations.</p>
          </list-item>
          <list-item>
            <p>Chronic granulomatous disease</p>
          </list-item>
          <list-item>
            <p>Hyperimmunoglobulin E recurrent infection syndrome (Job syndrome)</p>
          </list-item>
          <list-item>
            <p>X-linked CD40L deficiency (hyper-IgM syndrome)</p>
          </list-item>
        </list>
        <p>
<bold>Polygenetic modifiers </bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Fc gamma receptor (FCGR) II polymorphism</p>
          </list-item>
        </list>
        <p>
<bold>Comorbidities</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Sarcoidosis, autoimmune disease, steroid treatment</p>
          </list-item>
          <list-item>
            <p>Hepatic disease</p>
          </list-item>
          <list-item>
            <p>Solid organ transplant conditioning</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20152.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Approximately 1 million cases of cryptococcal meningitis are reported annually. The incidence have markedly&#x000a0;increased&#x000a0;since 1950s because of corticosteroid use and improvement of survival in cancer patients. However, most of the cryptococcal reports come from the 1980s and are predominantly AIDS-related cases. Approximately 6% of patients with AIDS develop cryptococcal infections, and patients with AIDS-associated cryptococcosis account for 85% of all patients diagnosed with cryptococcosis.&#x000a0;<xref ref-type="bibr" rid="article-20152.r2">[2]</xref><xref ref-type="bibr" rid="article-20152.r1">[1]</xref></p>
      </sec>
      <sec id="article-20152.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The organism is acquired by inhalation. After being deposited into the pulmonary alveoli, the yeast spores must survive the normal to high pH and the physiological concentrations of carbon dioxide before they are phagocytized by alveolar macrophages, a more acidic environment, and disseminated after a latent period of containment in the lung lymph nodes. The essential factor in the survival of <italic toggle="yes">C. neoformans </italic>in this extracellular environment is glucosylceramide synthase.&#x000a0;<xref ref-type="bibr" rid="article-20152.r5">[5]</xref></p>
        <p>The host response includes both cellular and humoral components. Possibly, the&#x000a0;eradication of Cryptococci relies on natural killer cells and antibody-dependent cell-mediated killing.&#x000a0;<xref ref-type="bibr" rid="article-20152.r6">[6]</xref></p>
        <p>While all organs can be involved, Cryptococcus spp. have a strong affinity for the central nervous system. This neurotropism is linked to several cryptococcal-specific factors which facilitate the permeability of the blood-brain barrier; between them, metalloproteinases and ureases&#x000a0;enzymes cause neuromodulation and mechanisms facilitate survival in the nutrient-deprived environment of the brain (autophagy and high-affinity sugar transporters).&#x000a0;<xref ref-type="bibr" rid="article-20152.r7">[7]</xref><xref ref-type="bibr" rid="article-20152.r8">[8]</xref></p>
        <p>There can be little or no necrosis or organ damage until later disease. In patients with heavy infections, organ dysfunction may be accelerated, primarily due to tissue distortion caused by the growing fungal burden.&#x000a0;<xref ref-type="bibr" rid="article-20152.r9">[9]</xref></p>
      </sec>
      <sec id="article-20152.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p><italic toggle="yes">C. neoformans </italic>reproduces by budding and forms round yeast-like cells that are 3 to 6 micrometers in diameter. In the host and culture media, each cell is surrounded by a large polysaccharide capsule that has antiphagocytic properties and may be immunosuppressive. It can form smooth, convex, yellow, or tan colonies on solid media at 20 to 37 degrees C. The non-pathogenic strains do not grow at this temperature.&#x000a0;<xref ref-type="bibr" rid="article-20152.r10">[10]</xref></p>
      </sec>
      <sec id="article-20152.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Cryptococcal meningitis usually presents as a subacute meningoencephalitis.&#x000a0;The patient&#x000a0;commonly&#x000a0;presents with neurological symptoms such as a headache, altered mental status,&#x000a0;and other&#x000a0;signs and symptoms include&#x000a0;lethargy along with fever, stiff neck (both associated with an aggressive inflammatory response),&#x000a0;nausea and vomiting. Some patients who are HIV positive may have minimal or nonspecific symptoms at presentation.</p>
        <p>The duration of symptoms from onset to a presentation is usually 1 to 2 weeks in HIV cases and 6 to 12 weeks in non-HIV cases.</p>
        <p>Visual symptoms include diplopia and photophobia at the onset,&#x000a0;and reduced acuity later&#x000a0;in the disease (due to high cerebrospinal fluid (CSF) pressure or compression of the optic nerve and tracts). Other findings include hearing defects, ataxia, aphasia, seizures, and chorea.</p>
        <p>Although <italic toggle="yes">C. neoformans</italic> enters the body through the lungs, the central nervous system (CNS) is the main site of evident clinical infection.&#x000a0;<xref ref-type="bibr" rid="article-20152.r4">[4]</xref></p>
      </sec>
      <sec id="article-20152.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The workup at initial evaluation should depend on CSF lab tests. However,&#x000a0;to prevent a post-dural puncture cerebral herniation,&#x000a0;a CT scan or MRI of the brain or a fundus examination should be considered before performing a lumbar puncture.&#x000a0;<xref ref-type="bibr" rid="article-20152.r4">[4]</xref></p>
        <p>Blood and CSF should be cultured for fungi and tested for cryptococcal antigen. Routine lab tests may be normal even with widespread disease. Opening pressure has to be measured at the first spinal tap, a pressure over 25 cm of water is a predictor of a poor prognosis.&#x000a0;<xref ref-type="bibr" rid="article-20152.r4">[4]</xref></p>
        <p>CSF usually presents low glucose and high protein levels. White cell count can be normal or higher than 20 microL and have a lymphocyte predominance. Nevertheless, CSF can be normal and have positive results on India ink stain and antigen testing (especially in HIV-positive patients who do not have an adequate inflammatory response).&#x000a0;<xref ref-type="bibr" rid="article-20152.r11">[11]</xref></p>
      </sec>
      <sec id="article-20152.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Treatment has not varied for a decade, according to recommendations from the 2010 IDSA (Infectious Diseases Society of America) update. The first-line antifungal treatment is based on the induction, consolidation, and maintenance of the following three types of patients<xref ref-type="bibr" rid="article-20152.r12">[12]</xref><xref ref-type="bibr" rid="article-20152.r9">[9]</xref>:</p>
        <p>
<bold>HIV-Related Disease</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><italic toggle="yes"><bold>Induction therapy</bold></italic>
<list list-type="bullet"><list-item><p>Amphotericin B deoxycholate (0.7 to 1.0 mg/kg/day) + flucytosine (100 mg/kg/day orally) for 2 weeks (A1 Evidence)</p></list-item><list-item><p>Liposomal amphotericin B (3 to 4 mg/kg/day) or amphotericin B lipid complex (5 mg/kg/day; kidney function surveillance) + flucytosine (100 mg/kg/day) for 2 weeks (B2 Evidence)</p></list-item><list-item><p>Amphotericin B deoxycholate (0.7 to 1.0 mg/kg/day) or liposomal amphotericin B&#x000a0;(3 to 4 mg/kg/day) or amphotericin B lipid complex (5 mg/kg/day, for patients who do not tolerate flucytosine) for 4 to 6 weeks (B2 Evidence)</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold><italic toggle="yes">Induction therapy alternatives</italic></bold>
<list list-type="bullet"><list-item><p>Amphotericin B deoxycholate&#x000a0;+ fluconazole (B1 Evidence)</p></list-item><list-item><p>Fluconazole + flucytosine (B2 Evidence)</p></list-item><list-item><p>Fluconazole (B2 Evidence)</p></list-item><list-item><p>Itraconazole (C2 Evidence)</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold><italic toggle="yes">Consolidation therapy</italic></bold>
<list list-type="bullet"><list-item><p>Fluconazole (400 mg/day) for 8 weeks (A1 Evidence)</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold><italic toggle="yes">Maintenance therapy</italic></bold>
<list list-type="bullet"><list-item><p>Fluconazole (200 mg/day) for 1 or more years (A1 Evidence)</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold><italic toggle="yes">Maintenance therapy alternatives</italic></bold>
<list list-type="bullet"><list-item><p>Itraconazole (400 mg/day) for 1 or more years (C1 Evidence)</p></list-item><list-item><p>Amphotericin B deoxycholate&#x000a0;(1 mg/kg/week) for 1 or more years (C1 Evidence)</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Transplant&#x000a0;Related Disease</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><italic toggle="yes"><bold>Induction therapy</bold></italic>
<list list-type="bullet"><list-item><p>Liposomal amphotericin B&#x000a0;(3 to 4 mg/kg/day) or amphotericin B lipid complex (5 mg/kg/day) + flucytosine (100 mg/kg/day) for 2 weeks (B3 Evidence)</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes"><bold>Induction therapy alternatives</bold></italic>
<list list-type="bullet"><list-item><p>Liposomal amphotericin B&#x000a0;(6 mg/kg/day) or amphotericin B lipid complex (5 mg/kg/day) for 4 to 6 weeks (B3 Evidence)</p></list-item><list-item><p>Amphotericin B deoxycholate&#x000a0;(0.7 mg/kg/day) for 4 to 6 weeks (B3 Evidence)</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes"><bold>Consolidation therapy</bold></italic>&#x000a0;
<list list-type="bullet"><list-item><p>Fluconazole (400 to 800 mg/day) for 8 weeks (B3 Evidence)</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes"><bold>Maintenance therapy</bold></italic>
<list list-type="bullet"><list-item><p>Fluconazole (200 to 400 mg/day) for 6 months to 1 year (B3 Evidence)</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Not HIV/Transplant Related Disease</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Induction therapy</bold>
<list list-type="bullet"><list-item><p>Amphotericin B deoxycholate&#x000a0;(0.7 to 1.0 mg/kg/day) + flucytosine (100 mg/kg/day) for 4 or more weeks (B2 Evidence)</p></list-item><list-item><p>Amphotericin B deoxycholate&#x000a0;(0.7 to 1.0 mg/kg/day) for 6 weeks (B2 Evidence)</p></list-item><list-item><p>Liposomal amphotericin B&#x000a0;(3 to 4 mg/kg/day) or amphotericin B lipid complex&#x000a0;(5 mg/kg/day) combined with flucytosine, 4 weeks (B3 Evidence)</p></list-item><list-item><p>Amphotericin B deoxycholate&#x000a0;(0.7 mg/kg/day) + flucytosine (100 mg/kg/day) for 2 weeks (B2 Evidence)</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes"><bold>Consolidation therapy</bold></italic>
<list list-type="bullet"><list-item><p>Fluconazole (400 to 800 mg/day) for 8 weeks (B3 Evidence)</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes"><bold>Maintenance therapy</bold></italic>
<list list-type="bullet"><list-item><p>Fluconazole (200 mg/day) for 6 to 12 months (B3 Evidence)</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>The combination of amphotericin B and flucytosine has proved the most effective measure to clear the infection, and it showed a greater survival&#x000a0;benefit over amphotericin alone. However, due to its cost, flucytosine is often unavailable in poor-resource settings where the disease burden is significant. Combinations of amphotericin B and fluconazole have been studied, and greater results have been found over amphotericin B alone.&#x000a0;<xref ref-type="bibr" rid="article-20152.r13">[13]</xref>,<xref ref-type="bibr" rid="article-20152.r14">[14]</xref>,<xref ref-type="bibr" rid="article-20152.r15">[15]</xref></p>
        <p>Without treatment, the clinical course progresses to confusion, seizures, reduced level of consciousness, and coma.</p>
        <p>Headache refractory to pain-killers can be treated with spinal decompression after an adequate neuroimaging evaluation with a CT scan or MRI. The safe maximum volume of CSF that can be drained at one lumbar puncture is unclear, but up to 30 mL are frequently removed with the pressure checked after each 10 mL removed.&#x000a0;<xref ref-type="bibr" rid="article-20152.r4">[4]</xref>,<xref ref-type="bibr" rid="article-20152.r16">[16]</xref></p>
      </sec>
      <sec id="article-20152.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis is based upon the following causes of intracranial mass lesions and infections<xref ref-type="bibr" rid="article-20152.r4">[4]</xref>:</p>
        <list list-type="bullet">
          <list-item>
            <p>Pyogenic, Nocardial or Aspergillus abscess</p>
          </list-item>
          <list-item>
            <p>Mycobacterium tuberculosis infection</p>
          </list-item>
          <list-item>
            <p>Histoplasma capsulatum infection</p>
          </list-item>
          <list-item>
            <p>Acanthamoeba infection</p>
          </list-item>
          <list-item>
            <p>Neurosyphilis</p>
          </list-item>
          <list-item>
            <p>Lymphomas, lymphocytic meningitis, meningeal metastases</p>
          </list-item>
          <list-item>
            <p>Hemorrhages</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20152.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The initial prognosis depends on mortality predictors such&#x000a0;as the following<xref ref-type="bibr" rid="article-20152.r2">[2]</xref>,<xref ref-type="bibr" rid="article-20152.r4">[4]</xref>,<xref ref-type="bibr" rid="article-20152.r17">[17]</xref>,<xref ref-type="bibr" rid="article-20152.r18">[18]</xref>:</p>
        <list list-type="bullet">
          <list-item>
            <p>CSF opening pressure of more than 25 cm of water</p>
          </list-item>
          <list-item>
            <p>Low CSF white cells count</p>
          </list-item>
          <list-item>
            <p>Sensory impairment</p>
          </list-item>
          <list-item>
            <p>Delayed diagnosis</p>
          </list-item>
          <list-item>
            <p>Elevated CSF antigen titers</p>
          </list-item>
          <list-item>
            <p>Rate of infection clearance</p>
          </list-item>
          <list-item>
            <p>CSF yeast count more than 10 mm^3 (a common practice in Brazil)<xref ref-type="bibr" rid="article-20152.r19">[19]</xref></p>
          </list-item>
          <list-item>
            <p>Non-HIV-related patients and the prognostic factors in these patients, in addition to the already mentioned:
<list list-type="bullet"><list-item><p>Markers of a poor inflammatory response</p></list-item><list-item><p>Absence of headache</p></list-item><list-item><p>Underlying hematological malignancy</p></list-item><list-item><p>Chronic renal or liver disease</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>Mortality varies from country to country depending on the resource settings. It remains high in the&#x000a0;United States and France, with a 10-week mortality of 15% to 26%, and it is even higher in non-HIV patients because of the delayed diagnosis and dysfunctional immune responses. On the other hand, in poor-resource countries, mortality increase from 30% to 70% in 10 weeks because of the late presentation and lack of access to drugs, manometers, and optimal monitoring.<xref ref-type="bibr" rid="article-20152.r12">[12]</xref></p>
      </sec>
      <sec id="article-20152.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Complications include the following<xref ref-type="bibr" rid="article-20152.r4">[4]</xref>:</p>
        <list list-type="bullet">
          <list-item>
            <p>Persistent Infection - Persistently positive results of cultures of CSF after 4 weeks of proven antifungal therapy at an established effective dose is a reasonable starting point.</p>
          </list-item>
          <list-item>
            <p>Relapsed Infection (based upon two main characteristics)
<list list-type="order"><list-item><p>The recovery of viable Cryptococci from a previously checked sterile body site is essential.</p></list-item><list-item><p>Recrudescence of signs and symptoms at the previous site of disease supports the presence of&#x000a0;disease.</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Elevated CSF Pressure - Acute elevated symptomatic CSF pressure (sometimes due to initial antifungal therapy) should be managed rapidly by decompression via repeated lumbar taps, transitory lumbar drainage catheter, or ventriculostomy in some patients.</p>
          </list-item>
          <list-item>
            <p>Immune Reconstitution Inflammatory Syndrome (IRIS):
<list list-type="bullet"><list-item><p><italic toggle="yes">Unmasking</italic> IRIS, in which cryptococcal symptoms appear after the initiation of antiretroviral therapy.</p></list-item><list-item><p><italic toggle="yes">Paradoxical</italic>&#x000a0;IRIS during the treatment of cryptococcosis and administration of antiretroviral therapy.</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>Cerebral cryptococcomas&#x000a0;can cause significant short- and long-term neurological complications. They are hard to treat and normally require a long-term antifungal therapy.</p>
        <p>Hydrocephalus is a later complication and can present as dementia or chronic headache.</p>
      </sec>
      <sec id="article-20152.s13" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>
<bold>HIV-Infected Patients</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>The incidence of cryptococcal meningitis has diminished in patients with antiretroviral therapy (ART).</p>
          </list-item>
          <list-item>
            <p>Symptoms typically begin insidiously during a 2-week period. The most common symptoms are fever, malaise, and headache. Cranial neuropathies may also be present. Symptoms like cough, dyspnea,&#x000a0;and skin rash suggest a disseminated disease.</p>
          </list-item>
          <list-item>
            <p>The antifungal prophylaxis is not recommended as a routine for cryptococcal disease (II-B Evidence).</p>
          </list-item>
        </list>
        <p>
<bold>Non-HIV-Infected Patients</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><italic toggle="yes">C. neoformans</italic> disseminates hematogenously from the respiratory tract and has a propensity for the central nervous system. The inflammatory response in the brain is usually milder than the one in bacterial meningitis. The inflammatory infiltrate is comprised of mononuclear cells predominantly with occasional polymorphonuclear leukocytes. Generally, brain involvement is diffuse but localized infection can occur (cryptococcoma).</p>
          </list-item>
          <list-item>
            <p>Most individuals with cryptococcal meningitis are immunocompromised. The most common cases include glucocorticoid therapy, organ transplantation, cancer, and other conditions&#x000a0;such as sarcoidosis and hepatic failure.</p>
          </list-item>
          <list-item>
            <p>Symptom presentation is variable. Some patients have symptoms for up to 2 to 8 months before diagnosis while others can present an acute illness in a few days. Approximately&#x000a0;50% of cases have fever. Generally, headache, lethargy, personality changes, and memory loss can appear over 2 to 4 weeks. Some patients can also present as a disseminated disease.</p>
          </list-item>
        </list>
        <p>The definitive diagnosis of cryptococcal meningitis is made by culture from the CSF. The opening pressure should be measured along with India ink evaluation, cryptococcal antigen testing, fungal culture, and routine spinal fluid studies. A positive cryptococcal antigen in the CSF or serum can strongly suggest the infection before the cultures become positive in high-risk patients.</p>
        <p>Neuroimaging must be performed prior to lumbar puncture if there is a concern for a high intracranial pressure.</p>
        <p>The principal antifungal agents for the treatment of cryptococcal meningitis are intravenous amphotericin B deoxycholate and its lipid formulations, oral flucytosine, and oral fluconazole. While amphotericin B and flucytosine are fungicidal, fluconazole is only fungistatic. Lipid formulations of amphotericin B are preferred on patients with renal dysfunction or at risk for renal failure.</p>
        <p>Cryptococcal meningitis is fatal if untreated. The therapeutic regime includes three phases: Induction&#x000a0;followed by&#x000a0;consolidation for a total of&#x000a0;10 weeks (to rapidly sterilize the CSF and to decrease early mortality) and maintenance therapy to prevent relapses.</p>
      </sec>
      <sec id="article-20152.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Cryptococcal meningitis is a serious disorder with high mortality and thus best managed by an interprofessional team that includes a radiologist, emergency department physician, internist, infectious disease specialist, infectious disease nurse, neurologist and a pharmacist. Patients are usually treated with two antifungal agents and the treatment duration can be as long as 6-24 months.</p>
        <p>Patients who are immunocompromised as well as those with neurological symptoms tend to have poor outcomes despite optimal treatment.</p>
      </sec>
      <sec id="article-20152.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20152&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20152">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/infectious-disease/cryptococcal-meningitis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=20152">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/20152/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=20152">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-20152.s16">
        <fig id="article-20152.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Expected CSF Findings in Bacterial versus Viral versus Fungal Meningitis 2 Contributed by Kenadeed Hersi</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Screenshot__2017-09-13__18.34.32" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-20152.s17">
        <fig id="article-20152.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Figure 3 has a reference of PMID 22844374, A case of carcinomatous meningitis despite prophylactic cranial irradiation in small cell lung cancer during treatment with amrubicin. Contributed by Ayesha Anwar, MBBS</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Fig__3" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-20152.s18">
        <fig id="article-20152.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Meningitis, Carcinomatous Flow Chart Contributed by Ayesha Anwar, MBBS</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Flow__Chart" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-20152.s19">
        <title>References</title>
        <ref id="article-20152.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>May</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Wiesner</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Bicanic</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nielsen</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Cryptococcus: from environmental saprophyte to global pathogen.</article-title>
            <source>Nat Rev Microbiol</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>106</fpage>
            <page-range>106-17</page-range>
            <pub-id pub-id-type="pmid">26685750</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20152.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pappas</surname>
                <given-names>PG</given-names>
              </name>
            </person-group>
            <article-title>Cryptococcal infections in non-HIV-infected patients.</article-title>
            <source>Trans Am Clin Climatol Assoc</source>
            <year>2013</year>
            <volume>124</volume>
            <fpage>61</fpage>
            <page-range>61-79</page-range>
            <pub-id pub-id-type="pmid">23874010</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20152.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Takahara</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Laz&#x000e9;ra</surname>
                <given-names>Mdos S</given-names>
              </name>
              <name>
                <surname>Wanke</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Trilles</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Dutra</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Paula</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Nakazato</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Anzai</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Leite J&#x000fa;nior</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Paula</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Hahn</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>First report on Cryptococcus neoformans in pigeon excreta from public and residential locations in the metropolitan area of Cuiab&#x000e1;, State of Mato Grosso, Brazil.</article-title>
            <source>Rev Inst Med Trop Sao Paulo</source>
            <year>2013</year>
            <season>Nov-Dec</season>
            <volume>55</volume>
            <issue>6</issue>
            <fpage>371</fpage>
            <page-range>371-6</page-range>
            <pub-id pub-id-type="pmid">24213188</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20152.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Williamson</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Jarvis</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Panackal</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Fisher</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Molloy</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Loyse</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Harrison</surname>
                <given-names>TS</given-names>
              </name>
            </person-group>
            <article-title>Cryptococcal meningitis: epidemiology, immunology, diagnosis and therapy.</article-title>
            <source>Nat Rev Neurol</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>13</fpage>
            <page-range>13-24</page-range>
            <pub-id pub-id-type="pmid">27886201</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20152.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rittershaus</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Kechichian</surname>
                <given-names>TB</given-names>
              </name>
              <name>
                <surname>Allegood</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Merrill</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Hennig</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Luberto</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Del Poeta</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Glucosylceramide synthase is an essential regulator of pathogenicity of Cryptococcus neoformans.</article-title>
            <source>J Clin Invest</source>
            <year>2006</year>
            <month>Jun</month>
            <volume>116</volume>
            <issue>6</issue>
            <fpage>1651</fpage>
            <page-range>1651-9</page-range>
            <pub-id pub-id-type="pmid">16741577</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20152.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schmidt</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zimmermann</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Tramsen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Koehl</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Lehrnbecher</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Natural killer cells and antifungal host response.</article-title>
            <source>Clin Vaccine Immunol</source>
            <year>2013</year>
            <month>Apr</month>
            <volume>20</volume>
            <issue>4</issue>
            <fpage>452</fpage>
            <page-range>452-8</page-range>
            <pub-id pub-id-type="pmid">23365210</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20152.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tham</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Uhrig</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Na Pombejra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jamklang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bautos</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Gelli</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Invasion of the central nervous system by Cryptococcus neoformans requires a secreted fungal metalloprotease.</article-title>
            <source>mBio</source>
            <year>2014</year>
            <month>Jun</month>
            <day>03</day>
            <volume>5</volume>
            <issue>3</issue>
            <fpage>e01101</fpage>
            <page-range>e01101-14</page-range>
            <pub-id pub-id-type="pmid">24895304</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20152.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stie</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fox</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Blood-brain barrier invasion by Cryptococcus neoformans is enhanced by functional interactions with plasmin.</article-title>
            <source>Microbiology (Reading)</source>
            <year>2012</year>
            <month>Jan</month>
            <volume>158</volume>
            <issue>Pt 1</issue>
            <fpage>240</fpage>
            <page-range>240-258</page-range>
            <pub-id pub-id-type="pmid">21998162</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20152.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Perfect</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Bicanic</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Cryptococcosis diagnosis and treatment: What do we know now.</article-title>
            <source>Fungal Genet Biol</source>
            <year>2015</year>
            <month>May</month>
            <volume>78</volume>
            <fpage>49</fpage>
            <page-range>49-54</page-range>
            <pub-id pub-id-type="pmid">25312862</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20152.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nyazika</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Hagen</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Meis</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Robertson</surname>
                <given-names>VJ</given-names>
              </name>
            </person-group>
            <article-title>Cryptococcus tetragattii as a major cause of cryptococcal meningitis among HIV-infected individuals in Harare, Zimbabwe.</article-title>
            <source>J Infect</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>72</volume>
            <issue>6</issue>
            <fpage>745</fpage>
            <page-range>745-752</page-range>
            <pub-id pub-id-type="pmid">27038502</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20152.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abassi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Boulware</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Rhein</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Cryptococcal Meningitis: Diagnosis and Management Update.</article-title>
            <source>Curr Trop Med Rep</source>
            <year>2015</year>
            <month>Jun</month>
            <day>01</day>
            <volume>2</volume>
            <issue>2</issue>
            <fpage>90</fpage>
            <page-range>90-99</page-range>
            <pub-id pub-id-type="pmid">26279970</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20152.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Perfect</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Dismukes</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Dromer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Goldman</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Graybill</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Hamill</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Harrison</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Larsen</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Lortholary</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Pappas</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Powderly</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sobel</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Sorrell</surname>
                <given-names>TC</given-names>
              </name>
            </person-group>
            <article-title>Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.</article-title>
            <source>Clin Infect Dis</source>
            <year>2010</year>
            <month>Feb</month>
            <day>01</day>
            <volume>50</volume>
            <issue>3</issue>
            <fpage>291</fpage>
            <page-range>291-322</page-range>
            <pub-id pub-id-type="pmid">20047480</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20152.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Day</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Chau</surname>
                <given-names>TTH</given-names>
              </name>
              <name>
                <surname>Wolbers</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mai</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Dung</surname>
                <given-names>NT</given-names>
              </name>
              <name>
                <surname>Mai</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>Phu</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>Nghia</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Phong</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Thai</surname>
                <given-names>CQ</given-names>
              </name>
              <name>
                <surname>Thai</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Chuong</surname>
                <given-names>LV</given-names>
              </name>
              <name>
                <surname>Sinh</surname>
                <given-names>DX</given-names>
              </name>
              <name>
                <surname>Duong</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Hoang</surname>
                <given-names>TN</given-names>
              </name>
              <name>
                <surname>Diep</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Sieu</surname>
                <given-names>TPM</given-names>
              </name>
              <name>
                <surname>Baker</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Chau</surname>
                <given-names>NVV</given-names>
              </name>
              <name>
                <surname>Hien</surname>
                <given-names>TT</given-names>
              </name>
              <name>
                <surname>Lalloo</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Farrar</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Combination antifungal therapy for cryptococcal meningitis.</article-title>
            <source>N Engl J Med</source>
            <year>2013</year>
            <month>Apr</month>
            <day>04</day>
            <volume>368</volume>
            <issue>14</issue>
            <fpage>1291</fpage>
            <page-range>1291-1302</page-range>
            <pub-id pub-id-type="pmid">23550668</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20152.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Campitelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zeineddine</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Samaha</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Maslak</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Combination Antifungal Therapy: A Review of Current Data.</article-title>
            <source>J Clin Med Res</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>9</volume>
            <issue>6</issue>
            <fpage>451</fpage>
            <page-range>451-456</page-range>
            <pub-id pub-id-type="pmid">28496543</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20152.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Merry</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Boulware</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Cryptococcal Meningitis Treatment Strategies Affected by the Explosive Cost of Flucytosine in the United States: A Cost-effectiveness Analysis.</article-title>
            <source>Clin Infect Dis</source>
            <year>2016</year>
            <month>Jun</month>
            <day>15</day>
            <volume>62</volume>
            <issue>12</issue>
            <fpage>1564</fpage>
            <page-range>1564-8</page-range>
            <pub-id pub-id-type="pmid">27009249</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20152.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beardsley</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wolbers</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kibengo</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Ggayi</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Kamali</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cuc</surname>
                <given-names>NT</given-names>
              </name>
              <name>
                <surname>Binh</surname>
                <given-names>TQ</given-names>
              </name>
              <name>
                <surname>Chau</surname>
                <given-names>NV</given-names>
              </name>
              <name>
                <surname>Farrar</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Merson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Phuong</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Thwaites</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Van Kinh</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Thuy</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Chierakul</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Siriboon</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Thiansukhon</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Onsanit</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Supphamongkholchaikul</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Heyderman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mwinjiwa</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>van Oosterhout</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Imran</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Basri</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mayxay</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dance</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Phimmasone</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rattanavong</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lalloo</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Day</surname>
                <given-names>JN</given-names>
              </name>
              <collab>CryptoDex Investigators</collab>
            </person-group>
            <article-title>Adjunctive Dexamethasone in HIV-Associated Cryptococcal Meningitis.</article-title>
            <source>N Engl J Med</source>
            <year>2016</year>
            <month>Feb</month>
            <day>11</day>
            <volume>374</volume>
            <issue>6</issue>
            <fpage>542</fpage>
            <page-range>542-54</page-range>
            <pub-id pub-id-type="pmid">26863355</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20152.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Panackal</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Wuest</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kosa</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Komori</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Blake</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Browne</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Rosen</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Hagen</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Meis</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Levitz</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Quezado</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hammoud</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bennett</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Bielekova</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Williamson</surname>
                <given-names>PR</given-names>
              </name>
            </person-group>
            <article-title>Paradoxical Immune Responses in Non-HIV Cryptococcal Meningitis.</article-title>
            <source>PLoS Pathog</source>
            <year>2015</year>
            <month>May</month>
            <volume>11</volume>
            <issue>5</issue>
            <fpage>e1004884</fpage>
            <pub-id pub-id-type="pmid">26020932</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20152.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jitmuang</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Panackal</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Williamson</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Bennett</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Dekker</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Zelazny</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Performance of the Cryptococcal Antigen Lateral Flow Assay in Non-HIV-Related Cryptococcosis.</article-title>
            <source>J Clin Microbiol</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>54</volume>
            <issue>2</issue>
            <fpage>460</fpage>
            <page-range>460-3</page-range>
            <pub-id pub-id-type="pmid">26607986</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20152.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vidal</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Gerhardt</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Peixoto de Miranda</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Dauar</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Oliveira Filho</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Penalva de Oliveira</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Boulware</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Role of quantitative CSF microscopy to predict culture status and outcome in HIV-associated cryptococcal meningitis in a Brazilian cohort.</article-title>
            <source>Diagn Microbiol Infect Dis</source>
            <year>2012</year>
            <month>May</month>
            <volume>73</volume>
            <issue>1</issue>
            <fpage>68</fpage>
            <page-range>68-73</page-range>
            <pub-id pub-id-type="pmid">22578940</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
